EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem
Grantová podpora
MC_UU_12023/28
Medical Research Council - United Kingdom
U10 CA098543
NCI NIH HHS - United States
MC_EX_G0400248
Medical Research Council - United Kingdom
U10 CA180899
NCI NIH HHS - United States
MC_EX_UU_G0400248
Medical Research Council - United Kingdom
MC_UU_12023/11
Medical Research Council - United Kingdom
PubMed
25421877
PubMed Central
PMC4304379
DOI
10.1093/annonc/mdu526
PII: S0923-7534(19)31377-8
Knihovny.cz E-zdroje
- Klíčová slova
- international collaboration, osteosarcoma, randomised controlled trial, trial conduct,
- MeSH
- cisplatina aplikace a dávkování škodlivé účinky MeSH
- dítě MeSH
- doxorubicin aplikace a dávkování škodlivé účinky MeSH
- etoposid aplikace a dávkování škodlivé účinky MeSH
- ifosfamid aplikace a dávkování škodlivé účinky MeSH
- interferon alfa aplikace a dávkování škodlivé účinky MeSH
- kombinovaná terapie MeSH
- kvalita života MeSH
- lidé MeSH
- methotrexát aplikace a dávkování škodlivé účinky MeSH
- mladiství MeSH
- mladý dospělý MeSH
- nádory kostí farmakoterapie chirurgie MeSH
- neoadjuvantní terapie MeSH
- osteosarkom farmakoterapie chirurgie MeSH
- polyethylenglykoly aplikace a dávkování škodlivé účinky MeSH
- protokoly antitumorózní kombinované chemoterapie terapeutické užití MeSH
- výzkumný projekt MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- Názvy látek
- cisplatina MeSH
- doxorubicin MeSH
- etoposid MeSH
- ifosfamid MeSH
- interferon alfa MeSH
- methotrexát MeSH
- PEG-IFN-SA MeSH Prohlížeč
- polyethylenglykoly MeSH
BACKGROUND: Four international study groups undertook a large study in resectable osteosarcoma, which included two randomised controlled trials, to determine the effect on survival of changing post-operative chemotherapy based on histological response. PATIENTS AND METHODS: Patients with resectable osteosarcoma aged ≤40 years were treated with the MAP regimen, comprising pre-operatively of two 5-week cycles of cisplatin 120 mg/m(2), doxorubicin 75 mg/m(2), methotrexate 12 g/m(2) × 2 (MAP) and post-operatively two further cycles of MAP and two cycles of just MA. Patients were randomised after surgery. Those with ≥10% viable tumour in the resected specimen received MAP or MAP with ifosfamide and etoposide. Those with <10% viable tumour were allocated to MAP or MAP followed by pegylated interferon. Longitudinal evaluation of quality of life was undertaken. RESULTS: Recruitment was completed to the largest osteosarcoma study to date in 75 months. Commencing March 2005, 2260 patients were registered from 326 centres across 17 countries. About 1334 of 2260 registered patients (59%) were randomised. Pre-operative chemotherapy was completed according to protocol in 94%. Grade 3-4 neutropenia affected 83% of cycles and 59% were complicated by infection. There were three (0.13%) deaths related to pre-operative chemotherapy. At definitive surgery, 50% of patients had at least 90% necrosis in the resected specimen. CONCLUSIONS: New models of collaboration are required to successfully conduct trials to improve outcomes of patients with rare cancers; EURAMOS-1 demonstrates achievability. Considerable regulatory, financial and operational challenges must be overcome to develop similar studies in the future. The trial is registered as NCT00134030 and ISRCTN 67613327.
British Columbia Children's Hospital University of British Columbia Vancouver Canada
Center for Clinical Trials University Hospital Münster Münster Germany
Children's Hospital of Philadelphia University of Pennsylvania School of Medicine Philadelphia
Children's Oncology Group Arcadia USA
Cincinnati Children's Hospital Medical Center Cincinnati
Cooperative Osteosarcoma Study Group Klinikum Stuttgart Olgahospital Stuttgart Germany
Dana Farber Cancer Institute Boston
Department of Oncology University College Hospital London UK
Department of Pathology Boston Children's Hospital Boston USA
Department of Pediatric Hematology Oncology University Hospital Prague Czech Republic
Department of Pediatric Radiology University Medical Center Hamburg Eppendorf Hamburg Germany
Department of Radiation Oncology Medical Center Hamburg Eppendorf Hamburg Germany
H Lee Moffit Cancer Centre and Research Institute Tampa
IWK Health Center Dalhousie University Halifax Canada
Lucile Salter Packard Childrens Hospital Stanford Palo Alto USA
Medical Research Council Clinical Trials Unit at University College London London UK
Memorial Sloan Kettering Cancer Center New?York
Memorial Sloan Kettering Cancer Center New?York Orthopedic Surgery Johns Hopkins Baltimore USA
Our Lady's Children's Hospital Dublin Ireland
Primary Children's Hospital and Huntsman Cancer Institute University of Utah Salt Lake City
Royal National Orthopaedic Hospital Stanmore Cancer Institute University College London London UK
Royal Orthopaedic Hospital Birmingham UK
Section of Pediatric Hematology Oncology Montefiore Medical Center Bronx USA
Skane University Hospital Lund University Lund Sweden
St Anna Children's Hospital Vienna Austria
Stanford University Medical Center Pediatric Hematology Oncology Palo Alto USA
Texas Children's Cancer Centre Baylor College of Medicine Houston
University Children's Hospital Basel Basel Switzerland
University Hospital Ghent Gent Belgium
Zobrazit více v PubMed
Whelan J, McTiernan A, Cooper N, et al. Incidence and survival of malignant bone sarcomas in England 1979–2007. Int J Cancer. 2011;131:E508–E517. PubMed
Marina N, Bielack S, Whelan J, et al. International collaboration is feasible in trials for rare conditions: the EURAMOS experience. Cancer Treat Res. 2009;152:339–353. PubMed
Rosen G, Murphy ML, Huvos AG, et al. Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer. 1976;37:1–11. PubMed
Bacci G, Picci P, Ruggieri P, et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. Cancer. 1990;65:2539–2553. PubMed
Whelan JS, Jinks RC, McTiernan A, et al. Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. Ann Oncol. 2012;23:1607–1616. PubMed PMC
Marina N, Bielack S, Whelan J, et al. International collaboration is feasible in trials for rare conditions: the EURAMOS experience. In: Jaffe N, Bruland OS, Bielack S, editors. Pediatric and Adolescent Osteosarcoma Series: Cancer Treatment and Research. Vol. 152. 2010. pp. 339–354. PubMed
Barlow CF, Priebe CJ, Mulliken JB, et al. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr. 1998;132:527–530. PubMed
Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004–2011. PubMed
Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a Pediatric Oncology Group trial. J Clin Oncol. 2002;20:426–433. PubMed
Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376. PubMed
Varni JW, Burwinkle TM, Katz ER, et al. The PedsQL in pediatric cancer: reliability and validity of the Pediatric Quality of Life Inventory Generic Core Scales, Multidimensional Fatigue Scale, and Cancer Module. Cancer. 2002;94:2090–2106. PubMed
Calaminus G, Weinspach S, Teske C, Gobel U. Quality of life in children and adolescents with cancer. First results of an evaluation of 49 patients with the PEDQOL questionnaire. Klin Padiatr. 2000;212:211–215. PubMed
Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_archive:2006. (28 Nov 2014, date last accessed)
George SL, Desu MM. Planning the size and duration of a clinical trial studying the time to some critical event. J Chronic Dis. 1974;27:15–24. PubMed
Ferrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 2005;23:8845–8852. PubMed
Le Deley MC, Guinebretiere JM, Gentet JC, et al. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer. 2007;43:752–761. PubMed
Lewis IJ, Nooij MA, Whelan J, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007;99:112–128. PubMed
Smeland S, Muller C, Alvegard TA, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer. 2003;39:488–494. PubMed
Whelan J, Patterson D, Perisoglou M, et al. The role of interferons in the treatment of osteosarcoma. Pediatr Blood Cancer. 2010;54:350–354. PubMed
Schwartz CL, Wexler LH, Devidas M, et al. P9754 therapeutic intensification in non-metastatic osteosarcoma: a COG trial. J Clin Oncol. 2004;22 Meeting Abstracts abstr 8514.
Gentet JC, Brunat-Mentigny M, Demaille MC, et al. Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. Eur J Cancer. 1997;33:232–237. PubMed
Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer. 1994;73:2506–2511. PubMed
Bielack SS. Osteosarcoma: time to move on? Eur J Cancer. 2010;46:1942–1945. PubMed
Fern L, Davies S, Eden T, et al. Rates of inclusion of teenagers and young adults in England into National Cancer Research Network clinical trials: report from the National Cancer Research Institute (NCRI) Teenage and Young Adult Clinical Studies Development Group. Br J Cancer. 2008;99:1967–1974. PubMed PMC
Fern LA, Lewandowski JA, Coxon KM, et al. Available, accessible, aware, appropriate, and acceptable: a strategy to improve participation of teenagers and young adults in cancer trials. Lancet Oncol. 2014;15:e341–e350. PubMed
McTiernan A, Jinks RC, Sydes MR, et al. Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup. Eur J Cancer. 2012;48:703–712. PubMed PMC
Pearce S, Lavender V, Brownsdon A, et al. Perceptions of participants and professionals in bone sarcoma clinical trials: implications for study design and conduct. Eur J Cancer. 2013;49(suppl 2):A3819.
Bielack S, Smeland S, Whelan J, et al. MAP plus maintenance pegylated interferon α-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 “good response” randomization. J Clin Oncol. 2013;31(suppl):LBA10504. PubMed PMC
Osteosarcomas of the hand and foot: A sarcoma‑center case series experience
ClinicalTrials.gov
NCT00134030